Proton pump inhibitors (PPI) are inconsistently associated with osteoporotic fractures.
Barrett's esophagus patients are treated with high PPI doses for prolonged periods, but there are limited data on the incidence of osteoporosis and fractures in this group pf patients.
Dr Kumar and colleagues estimated the incidence of low bone mass related fractures in a population-based Barrett's esophagus cohort.
All subjects with Barrett's esophagus and a diagnosis of osteoporosis and fractures were identified using Rochester Epidemiology Project resources.
|22% had fractures|
|Alimentary Pharmacology & Therapeutics|
The incidence rates of all and osteoporotic fractures in these subjects were compared to an age- and gender similar population in Olmsted County to determine standardized incidence ratios.
Predictors were assessed using Cox proportional hazards models.
The researchers included 521 patients were included of whom 22% had fractures, and 9% had osteoporotic fractures.
The research team noted that the incidence of all fractures and osteoporotic fractures was comparable to that of an age- and gender-matched population.
The researchers found that PPI use, dose or duration of use was not associated with osteoporotic fracture risk.
Independent risk factors for osteoporotic fractures included older age, female gender and higher co-morbidity index.
Dr Kumar's team concludes, "The incidence of osteoporotic fractures was not increased in Barrett's esophagus patients compared to the general population."
"In addition, PPI use was not associated with increased fracture risk regardless of the duration of therapy or dose."